139 related articles for article (PubMed ID: 37949483)
21. Differences in Clinical Manifestations and Tumor Features Between Metastatic Pheochromocytoma/Paraganglioma Patients With and Without Germline SDHB Mutation.
Cui Y; Ma X; Wang F; Wang H; Zhou T; Chen S; Tong A; Li Y
Endocr Pract; 2021 Apr; 27(4):348-353. PubMed ID: 34024343
[TBL] [Abstract][Full Text] [Related]
22. Pediatric patients with pheochromocytoma and paraganglioma should have routine preoperative genetic testing for common susceptibility genes in addition to imaging to detect extra-adrenal and metastatic tumors.
Babic B; Patel D; Aufforth R; Assadipour Y; Sadowski SM; Quezado M; Nilubol N; Prodanov T; Pacak K; Kebebew E
Surgery; 2017 Jan; 161(1):220-227. PubMed ID: 27865588
[TBL] [Abstract][Full Text] [Related]
23. SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma.
Assadipour Y; Sadowski SM; Alimchandani M; Quezado M; Steinberg SM; Nilubol N; Patel D; Prodanov T; Pacak K; Kebebew E
Surgery; 2017 Jan; 161(1):230-239. PubMed ID: 27839933
[TBL] [Abstract][Full Text] [Related]
24. Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD.
Ricketts CJ; Forman JR; Rattenberry E; Bradshaw N; Lalloo F; Izatt L; Cole TR; Armstrong R; Kumar VK; Morrison PJ; Atkinson AB; Douglas F; Ball SG; Cook J; Srirangalingam U; Killick P; Kirby G; Aylwin S; Woodward ER; Evans DG; Hodgson SV; Murday V; Chew SL; Connell JM; Blundell TL; Macdonald F; Maher ER
Hum Mutat; 2010 Jan; 31(1):41-51. PubMed ID: 19802898
[TBL] [Abstract][Full Text] [Related]
25. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas.
Amar L; Baudin E; Burnichon N; Peyrard S; Silvera S; Bertherat J; Bertagna X; Schlumberger M; Jeunemaitre X; Gimenez-Roqueplo AP; Plouin PF
J Clin Endocrinol Metab; 2007 Oct; 92(10):3822-8. PubMed ID: 17652212
[TBL] [Abstract][Full Text] [Related]
26. An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis.
van Nederveen FH; Gaal J; Favier J; Korpershoek E; Oldenburg RA; de Bruyn EM; Sleddens HF; Derkx P; Rivière J; Dannenberg H; Petri BJ; Komminoth P; Pacak K; Hop WC; Pollard PJ; Mannelli M; Bayley JP; Perren A; Niemann S; Verhofstad AA; de Bruïne AP; Maher ER; Tissier F; Méatchi T; Badoual C; Bertherat J; Amar L; Alataki D; Van Marck E; Ferrau F; François J; de Herder WW; Peeters MP; van Linge A; Lenders JW; Gimenez-Roqueplo AP; de Krijger RR; Dinjens WN
Lancet Oncol; 2009 Aug; 10(8):764-71. PubMed ID: 19576851
[TBL] [Abstract][Full Text] [Related]
27. Targeting pheochromocytoma/paraganglioma with polyamine inhibitors.
Rai SK; Bril F; Hatch HM; Xu Y; Shelton L; Kalavalapalli S; Click A; Lee D; Beecher C; Kirby A; Kong K; Trevino J; Jha A; Jatav S; Kriti K; Luthra S; Garrett TJ; Guingab-Cagmat J; Plant D; Bose P; Cusi K; Hromas RA; Tischler AS; Powers JF; Gupta P; Bibb J; Beuschlein F; Robledo M; Calsina B; Timmers H; Taieb D; Kroiss M; Richter S; Langton K; Eisenhofer G; Bergeron R; Pacak K; Tevosian SG; Ghayee HK
Metabolism; 2020 Sep; 110():154297. PubMed ID: 32562798
[TBL] [Abstract][Full Text] [Related]
28. Failure of MIBG scan to detect metastases in SDHB-mutated pediatric metastatic pheochromocytoma.
Sait S; Pandit-Taskar N; Modak S
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28409892
[No Abstract] [Full Text] [Related]
29. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations.
Neumann HP; Pawlu C; Peczkowska M; Bausch B; McWhinney SR; Muresan M; Buchta M; Franke G; Klisch J; Bley TA; Hoegerle S; Boedeker CC; Opocher G; Schipper J; Januszewicz A; Eng C;
JAMA; 2004 Aug; 292(8):943-51. PubMed ID: 15328326
[TBL] [Abstract][Full Text] [Related]
30. Increased expression of Nrf2 and elevated glucose uptake in pheochromocytoma and paraganglioma with SDHB gene mutation.
Kamai T; Murakami S; Arai K; Nishihara D; Uematsu T; Ishida K; Kijima T
BMC Cancer; 2022 Mar; 22(1):289. PubMed ID: 35300626
[TBL] [Abstract][Full Text] [Related]
31. Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas.
Cassol CA; Winer D; Liu W; Guo M; Ezzat S; Asa SL
Mod Pathol; 2014 Aug; 27(8):1050-62. PubMed ID: 24390213
[TBL] [Abstract][Full Text] [Related]
32. Development and internal validation of a novel predictive model for
Zhou Y; Gao Y; Ma X; Li T; Cui Y; Wang Y; Li M; Zhang D; Tong A
Front Endocrinol (Lausanne); 2023; 14():1285631. PubMed ID: 38179299
[TBL] [Abstract][Full Text] [Related]
33. [
Prado-Wohlwend S; Del Olmo-García MI; Bello-Arques P; Merino-Torres JF
Front Endocrinol (Lausanne); 2022; 13():778322. PubMed ID: 35197929
[TBL] [Abstract][Full Text] [Related]
34. The utility of SDHB and FH immunohistochemistry in patients evaluated for hereditary paraganglioma-pheochromocytoma syndromes.
Udager AM; Magers MJ; Goerke DM; Vinco ML; Siddiqui J; Cao X; Lucas DR; Myers JL; Chinnaiyan AM; McHugh JB; Giordano TJ; Else T; Mehra R
Hum Pathol; 2018 Jan; 71():47-54. PubMed ID: 29079178
[TBL] [Abstract][Full Text] [Related]
35. Succinate: A Serum Biomarker of SDHB-Mutated Paragangliomas and Pheochromocytomas.
Lamy C; Tissot H; Faron M; Baudin E; Lamartina L; Pradon C; Al Ghuzlan A; Leboulleux S; Perfettini JL; Paci A; Hadoux J; Broutin S
J Clin Endocrinol Metab; 2022 Sep; 107(10):2801-2810. PubMed ID: 35948272
[TBL] [Abstract][Full Text] [Related]
36. SDHB-related pheochromocytoma and paraganglioma penetrance and genotype-phenotype correlations.
Jochmanova I; Wolf KI; King KS; Nambuba J; Wesley R; Martucci V; Raygada M; Adams KT; Prodanov T; Fojo AT; Lazurova I; Pacak K
J Cancer Res Clin Oncol; 2017 Aug; 143(8):1421-1435. PubMed ID: 28374168
[TBL] [Abstract][Full Text] [Related]
37. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status.
Eisenhofer G; Lenders JW; Siegert G; Bornstein SR; Friberg P; Milosevic D; Mannelli M; Linehan WM; Adams K; Timmers HJ; Pacak K
Eur J Cancer; 2012 Jul; 48(11):1739-49. PubMed ID: 22036874
[TBL] [Abstract][Full Text] [Related]
38. SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma.
Perez K; Jacene H; Hornick JL; Ma C; Vaz N; Brais LK; Alexander H; Baddoo W; Astone K; Esplin ED; Garcia J; Halperin DM; Kulke MH; Chan JA
Endocr Relat Cancer; 2022 Sep; 29(9):533-544. PubMed ID: 35731023
[TBL] [Abstract][Full Text] [Related]
39. Germline SDHB mutations are common in patients with apparently sporadic sympathetic paragangliomas.
Klein RD; Jin L; Rumilla K; Young WF; Lloyd RV
Diagn Mol Pathol; 2008 Jun; 17(2):94-100. PubMed ID: 18382370
[TBL] [Abstract][Full Text] [Related]
40. Clinical characteristics and outcomes of SDHB-related pheochromocytoma and paraganglioma in children and adolescents.
Jochmanova I; Abcede AMT; Guerrero RJS; Malong CLP; Wesley R; Huynh T; Gonzales MK; Wolf KI; Jha A; Knue M; Prodanov T; Nilubol N; Mercado-Asis LB; Stratakis CA; Pacak K
J Cancer Res Clin Oncol; 2020 Apr; 146(4):1051-1063. PubMed ID: 32062700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]